Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Simcere Secures Greater China Rights to Reyoung Bio’s Long‑Acting RSV Antibody RB0026 Under Priority Review

Fineline Cube Aug 20, 2026
Company Deals

VectorBuilder and Lir Therapeutics Forge AI Collaboration to Optimize AAV Capsids for Clinical Translation

Fineline Cube Aug 20, 2026
Company Deals

LEO Pharma to Acquire Global Rights to Dersimelagon From Tanabe – Late‑Stage Oral Therapy for Rare Protoporphyrias Nears FDA Decision

Fineline Cube Aug 20, 2026
Company Deals

Bio-Thera Solutions Expands Partnership with Avalon Pharma: Exclusive MENA Licensing Deal for Dupixent Biosimilar BAT2406 – Second Collaboration After BAT3306

Fineline Cube Aug 19, 2026
Company Deals

OmniAb Signs Global Collaboration and License Agreement with Eli Lilly for Ion Channel Program – Up to $370 Million in Milestones Plus Royalties

Fineline Cube Aug 18, 2026
Company Policy / Regulatory

China’s CDE Opens Public Comment on “Pioneer Program” for Cell and Gene Therapy Products, Capping Intake at 15 Drugs Per Year

Fineline Cube Aug 20, 2026
Company Drug

Abbisko Wins NMPA IND Clearance for Pan‑KRAS Inhibitor ABSK211 in Advanced Solid Tumors, Following FDA Green Light

Fineline Cube Aug 20, 2026
Company Drug

Haisco Pharmaceutical Wins NMPA Clinical Approval for Nav1.8 Inhibitor HSK51155 – Pain Drug Licensed to AbbVie in USD 700 Million Deal Advances in China

Fineline Cube Aug 19, 2026
Company Deals

Henlius Biotech and Palleon Pharmaceuticals Modify Licensing Agreement for Bifunctional Antibody

Fineline Cube May 22, 2024

Shanghai Henlius Biotech Inc., (HKG: 2696), a leading biopharmaceutical company based in China, has announced...

Company Legal / IP

GSK Confronted with Whistleblower Allegations Over Zantac and NDMA Link

Fineline Cube May 22, 2024

GlaxoSmithKline (GSK; NYSE: GSK), the UK-based pharmaceutical giant, is facing legal action in the form...

Company Deals

Astellas Pharma Considers Joint Cell Therapy Platform with Yaskawa Electric

Fineline Cube May 22, 2024

Astellas Pharma Inc. (TYO: 4503), a leading Japanese pharmaceutical company, has announced that it is...

Company Deals

Sanofi Leads Pharma Industry with AI Collaboration with Formation Bio and OpenAI

Fineline Cube May 22, 2024

Sanofi (NASDAQ: SNY), the France-based multinational pharmaceutical company, has announced a cutting-edge collaboration with US...

Company Drug

Eli Lilly’s Tirzepatide Earns China Approval for Type 2 Diabetes Treatment

Fineline Cube May 21, 2024

Eli Lilly & Co. (NYSE: LLY), a leading US pharmaceutical company, has announced that it...

Company Deals

Blue Sail Medical Subsidiary Secures RMB 100 Million Investment to Expand Operations

Fineline Cube May 21, 2024

China’s Blue Sail Medical Co., Ltd (SHE: 002382) has announced that Blue Sail Biosensors Medical...

Company Deals

Jiayue Pharmaceutical’s JYP0015 Secures $365 Million Licensing Agreement with Erasca

Fineline Cube May 21, 2024

Guangzhou Jiayue Pharmaceutical Technology Co., Ltd, a Chinese pharmaceutical company, has entered into a licensing...

Policy / Regulatory

China’s CDE Reports Record High in Clinical Trials for Innovative Drugs in 2023

Fineline Cube May 21, 2024

The Center for Drug Evaluation (CDE) has released its annual report, highlighting the growth in...

Company Drug

Gilead’s Seladelpar Shows Interim Benefits in PBC-Related Itch Clinical Trial

Fineline Cube May 21, 2024

Gilead Sciences (NASDAQ: GILD) has announced interim results from a long-term study assessing the safety...

Company

AstraZeneca Commits $1.5 Billion to Build Singapore-Based ADC Manufacturing Facility

Fineline Cube May 21, 2024

UK pharmaceutical company AstraZeneca (AZ; NASDAQ: AZN) has announced plans for a $1.5 billion greenfield...

Policy / Regulatory

NHSA Unveils 2024 Medical Procurement Overhaul, Aiming for Synergy Between National and Provincial Levels

Fineline Cube May 21, 2024

The National Healthcare Security Administration (NHSA) has issued a notification detailing plans to enhance the...

Company Medical Device

BGI Genomics Delays Market Filing for BRCA1/2 Detection Kit Due to Incomplete Data

Fineline Cube May 21, 2024

BGI Genomics Co., Ltd (SHE: 300676), a leading genomics company based in China, has announced...

Company Medical Device

Hymson Laser’s Mid Infrared Femtosecond Laser Technology Makes Medical Industry Inroads

Fineline Cube May 21, 2024

Shenzhen-based Hymson Laser Technology Group Co., Ltd (SHA: 688559) has announced a significant breakthrough with...

Company Drug

BMS’s Sotyktu Sustains Clinical Response in Long-Term Psoriasis Treatment

Fineline Cube May 21, 2024

Bristol Myers Squibb (BMS; NYSE: BMY) has announced the release of long-term clinical data for...

Policy / Regulatory

China and South Korea Reinforce Ties with Renewed MOU on Pharmaceuticals and Cosmetics Regulation

Fineline Cube May 21, 2024

The National Medical Products Administration (NMPA) of China and the Ministry of Food and Drug...

Company Deals

Pharmaron and AstraZeneca Enter Sweeping Partnership to Span Drug Development Services

Fineline Cube May 21, 2024

Pharmaron Beijing Co., Ltd, a leading Contract Research Organization (CRO) based in Beijing (HKG: 3759;...

Company Drug

Jiangsu Hengrui’s SHR1905 Anti-TSLP mAb Gets Green Light for COPD Clinical Trial

Fineline Cube May 21, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a prominent Chinese pharmaceutical company, announced that it...

Company Drug

Innovent Biologics’ IBI311 New Drug Application Accepted for Review by China’s CDE

Fineline Cube May 21, 2024

Innovent Biologics Inc., (HKG: 1801), a leading biopharmaceutical company in China, has announced that the...

Company Deals Digital Hospital

Union Hospital Teams Up with Baidu Health for AI-Enhanced Outpatient Services

Fineline Cube May 20, 2024

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, has entered into a...

Company Drug

Zai Lab and Innoviva Win China Approval for SUL-DUR to Treat Hospital-Acquired Pneumonia

Fineline Cube May 20, 2024

Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688), a China-based biopharmaceutical company, in collaboration with US...

Posts pagination

1 … 402 403 404 … 710

Recent updates

  • Simcere Secures Greater China Rights to Reyoung Bio’s Long‑Acting RSV Antibody RB0026 Under Priority Review
  • China’s CDE Opens Public Comment on “Pioneer Program” for Cell and Gene Therapy Products, Capping Intake at 15 Drugs Per Year
  • CARsgen 1H 2026: Satricabtagene Autoleucel Wins NMPA Approval as World’s First CAR‑T for Solid Tumors; Cash Runway Seen Into 2030
  • Abbisko Wins NMPA IND Clearance for Pan‑KRAS Inhibitor ABSK211 in Advanced Solid Tumors, Following FDA Green Light
  • VectorBuilder and Lir Therapeutics Forge AI Collaboration to Optimize AAV Capsids for Clinical Translation
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Simcere Secures Greater China Rights to Reyoung Bio’s Long‑Acting RSV Antibody RB0026 Under Priority Review

Company Policy / Regulatory

China’s CDE Opens Public Comment on “Pioneer Program” for Cell and Gene Therapy Products, Capping Intake at 15 Drugs Per Year

Company

CARsgen 1H 2026: Satricabtagene Autoleucel Wins NMPA Approval as World’s First CAR‑T for Solid Tumors; Cash Runway Seen Into 2030

Company Drug

Abbisko Wins NMPA IND Clearance for Pan‑KRAS Inhibitor ABSK211 in Advanced Solid Tumors, Following FDA Green Light

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.